Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma

Abstract

AbbreviationsHNSCC, head and neck squamous cell carcinoma; FOXM1, forkhead box M1; CEP55, centrosomal protein 55; HELLS, lymphoid specific helicase; qPCR, absolute real time reverse transcription quantitative polymerase chain reaction; NHOK, primary normal human oral keratinocytes; LnMet, lymph node metastasis; FFPE, formalin-fixed paraffin embedded. ABSTRACTWe recently showed that upregulation of a key oncogene FOXM1 precedes head and neck squamous cell carcinoma (HNSCC) malignancy. Furthermore, we also identified a centrosomal protein CEP55 and a DNA helicase/putative stem cell marker HELLS, which are both downstream targets of FOXM1.In this study, we have investigated the expression profiles of CEP55 and HELLS using immunohistochemistry and quantified by digital densitometry in a tissue panel (20 samples) consisting of normal oral mucosa, dysplasias, HNSCC and lymph node metastasis (LnMet) samples.Furthermore, we corroborated our findings using absolute real-time PCR (qPCR) on a panel of 12 primary normal human oral keratinocytes, 5 dysplasia and 10 HNSCC cell lines. Finally, we validated our study using bioinformatics microarray analysis on an independent HNSCC patient cohort (4 normal and 16 tumours). In normal oral mucosa, CEP55 protein was detected at very low level within the upper differentiated layers. In contrast, CEP55 was highly expressed in oral dysplasia whereas only moderate expression was detected in HNSCC and LnMet. Low level of HELLS expression was detected in the basal cell layer of the normal oral mucosa, moderate level was seen in dysplasia and high levels in both HNSCC and LnMet. These expression patterns were consistent with both qPCR data from the cell line panel and microarray data analysis of TNM-stage defined HNSCC samples confirming the progressive expression pattern of CEP55 and HELLS. To our knowledge, this is the first pilot study demonstrating that both CEP55 and HELLS mRNA and protein expression positively correlate with pre-malignancy and HNSCC progression. This study provides strong evidence that CEP55 and HELLS may be used in conjunction with FOXM1 as a biomarker set for early cancer detection and indicators of malignant conversion and progression.

Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase

“…Reports show that LSH contributes to the malignant progression of prostate cancer, melanoma, head and neck cancer, etc. (12,40,41); however, the molecular mechanisms are not well understood. Here, we demonstrated that LSH was linked to cancer progression of NPC.…”

Coassembled nanostructured bioscaffold reduces the expression of proinflammatory cytokines to induce apoptosis in epithelial cancer cells

“…The uncontrolled G2 to M cell cycle progression is essential for oral cancer progression, and is characterised by an increase in the tumour size 43 . The transcription factors associated with this pathway, PLK1 and FOXM1, activate CEP55, a cytokinesis promoter identified as a key marker of tumor formation and progression 44 . Earlier CEP55…”

Gene profiling suggests a common evolution of bladder cancer subtypes

“…Although these genes may be upregulated simply due to increased proliferative capacity of carcinomas, aurora kinase A has been previously investigated in UCa, where it is commonly found to be amplified [13] and may be a potential novel therapeutic target [14], which validates our results. A second category of upregulated genes included nicotine-responsive genes, as identified in both lung and head and neck squamous cancers, and include TTK , CEP55 , PRC1 and FOXM1 [15-18]. As tobacco smoking is a preeminent risk factor for the development of both UCa and SCCa of the bladder, these genes may reflect this association.…”